Chih Liang Chin

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. ncbi Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals
    Chih Liang Chin
    Translational Imaging, Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    J Pharmacol Exp Ther 336:709-15. 2011
  2. ncbi Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089
    Chih Liang Chin
    Advanced Technology, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    J Pharmacol Exp Ther 336:716-23. 2011
  3. ncbi Distinct spatiotemporal pattern of CNS lesions revealed by USPIO-enhanced MRI in MOG-induced EAE rats implicates the involvement of spino-olivocerebellar pathways
    Chih Liang Chin
    Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    J Neuroimmunol 211:49-55. 2009
  4. ncbi Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia
    Chih Liang Chin
    Advanced Technology, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Synapse 65:393-403. 2011
  5. ncbi Default-mode-like network activation in awake rodents
    Jaymin Upadhyay
    Translational Sciences, Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois, United States of America
    PLoS ONE 6:e27839. 2011
  6. ncbi Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection
    Scott Baker
    Translational Sciences, Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA
    J Pharmacol Exp Ther 341:263-73. 2012
  7. ncbi Paradigm shift in translational neuroimaging of CNS disorders
    Unal Sakoglu
    Translational Imaging Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Biochem Pharmacol 81:1374-87. 2011
  8. ncbi Pharmacological MRI in awake rats predicts selective binding of alpha4beta2 nicotinic receptors
    Chih Liang Chin
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Synapse 62:159-68. 2008
  9. ncbi Potentiation of analgesic efficacy but not side effects: co-administration of an ?4?2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats
    Chang Z Zhu
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 3500, USA
    Biochem Pharmacol 82:967-76. 2011
  10. ncbi Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and
    Betty B Yao
    Neurological Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, R47W, AP9A, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Pharmacol Exp Ther 328:141-51. 2009

Detail Information

Publications11

  1. ncbi Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals
    Chih Liang Chin
    Translational Imaging, Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    J Pharmacol Exp Ther 336:709-15. 2011
    ..The [corrected] region-specific brain activations observed in this ketamine phMRI study may afford a method of confirming central activity and dose selection in early clinical trials for novel experimental therapeutics. [corrected]..
  2. ncbi Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089
    Chih Liang Chin
    Advanced Technology, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    J Pharmacol Exp Ther 336:716-23. 2011
    ..Our data demonstrate the feasibility of predicting plasma exposures using a two-compartment pharmacokinetic model and its potential for optimizing dosing regimens...
  3. ncbi Distinct spatiotemporal pattern of CNS lesions revealed by USPIO-enhanced MRI in MOG-induced EAE rats implicates the involvement of spino-olivocerebellar pathways
    Chih Liang Chin
    Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    J Neuroimmunol 211:49-55. 2009
    ..Collectively, our results provide new insights into the pathophysiology of this animal model of MS...
  4. ncbi Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia
    Chih Liang Chin
    Advanced Technology, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Synapse 65:393-403. 2011
    ..The MAM model incorporating noninvasive imaging techniques may therefore serve as an improved translational research tool for assessing new treatments for schizophrenia...
  5. ncbi Default-mode-like network activation in awake rodents
    Jaymin Upadhyay
    Translational Sciences, Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois, United States of America
    PLoS ONE 6:e27839. 2011
    ..This investigation demonstrates that the cingulate is an important component of both the rodent DMN-like and anxiety networks...
  6. ncbi Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection
    Scott Baker
    Translational Sciences, Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA
    J Pharmacol Exp Ther 341:263-73. 2012
    ....
  7. ncbi Paradigm shift in translational neuroimaging of CNS disorders
    Unal Sakoglu
    Translational Imaging Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Biochem Pharmacol 81:1374-87. 2011
    ..In this paper, we review recent developments in structural and functional MRI and their use to probe functional connectivity in various CNS disorders such as schizophrenia, mood disorders, Alzheimer's disease (AD) and pain...
  8. ncbi Pharmacological MRI in awake rats predicts selective binding of alpha4beta2 nicotinic receptors
    Chih Liang Chin
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Synapse 62:159-68. 2008
    ..Our data demonstrate the utility of using phMRI in awake animals to characterize selective pharmacological action but also highlight an important confound (anesthesia) that is rarely considered in preclinical phMRI studies...
  9. ncbi Potentiation of analgesic efficacy but not side effects: co-administration of an ?4?2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats
    Chang Z Zhu
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 3500, USA
    Biochem Pharmacol 82:967-76. 2011
    ....
  10. ncbi Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and
    Betty B Yao
    Neurological Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, R47W, AP9A, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Pharmacol Exp Ther 328:141-51. 2009
    ..These data demonstrate that A-836339 is a useful tool for use of studying CB(2) receptor pharmacology and for investigation of the role of CB(2) receptor modulation for treatment of pain in preclinical animal models...
  11. ncbi Translational neuroimaging of the CNS: novel pathways to drug development
    Gerard B Fox
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064
    Mol Interv 9:302-13. 2009
    ..In this brief review, we highlight examples of the new wave of neuroimaging studies that engender useful biomarkers of disease for translational research...